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short duration, infection of immunocompromised hosts can 
result in serious and prolonged diarrheal illness [4].
Little is known about of the complex relationship 
between the large number of norovirus strains and host 
protective immunity. The lack of a cell culture or small 
animal model for human norovirus infection renders the 
study of neutralizing antibodies impossible. Measure-
ment of the ability of an antibody to “block” binding of a 
virus-like particle (VLP) to a carbohydrate ligand can be 
used as a surrogate neutralization assay [3, 5]. Using this 
method it has been shown that an increased antibody block-
ade titer is associated with protection from infection and 
decreased symptoms in non-immunocompromised norovi-
rus challenged volunteers [6, 7]. This phenomenon has not 
been studied in immunocompromised hosts. We present 
data showing that strain-specific antibody blockade titers 
do correlate with decreased symptoms and virus shed-
ding in a patient with chronic norovirus disease in the set-
ting of underlying immunocompromise due to lymphoma 
treatment.
Case
A 64-year-old female with follicular non-Hodgkin’s lym-
phoma had been receiving monthly chemotherapy with 
rituximab-bendamustine when she developed persis-
tent large volume watery diarrhea without associated 
fever, abdominal pain, nausea or vomiting a week before 
receiving her fifth out of six planned cycles of treatment. 
Colonoscopy, stool cultures for bacterial enteric patho-
gens and stool exam for ova and parasites were nega-
tive 2 weeks after the onset of diarrhea, but testing for 
norovirus by reverse transcriptase polymerase chain reac-
tion returned positive (Fig. 1). The patient did not receive 
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Introduction
Noroviruses are the most common cause of non-bacterial 
gastroenteritis worldwide, with around 21 million cases 
occurring annually in the United States alone [1]. Three 
norovirus genogroups (I, II, and IV) infect humans, and 
are further organized into more than 30 genetic clusters 
[2]. A single genetic cluster, the GII.4 noroviruses, cur-
rently accounts for greater than 80 % of all infections in 
the US [3]. The major capsid protein of GII.4 strains is 
evolving rapidly, resulting in new epidemic strains with 
altered antigenic sites [3]. Usually a self-limiting disease of 
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immunosuppressive medication after completion of her 
chemotherapy. Symptomatic treatment with loperamide 
16 mg/day and tincture of opium 24 mg/day was used, 
leading to a reduction of stool counts from 10–15 to 5 per 
day. Attempts to taper treatment resulted in increased stool 
counts. Neither treatment with nitazoxanide 500 mg twice 
daily for 7 days [8] 5 months post chemotherapy, nor infu-
sion of intravenous immunoglobulin (IVIG) 1 g/kg at 6 and 
6.5 months post chemotherapy resulted in a change of stool 
pattern. The patient was able to slowly taper the amount 
of antidiarrheal medications 8 months after completion of 
chemotherapy, and was off of all antidiarrheal medications 
by 10 months.
Methods
Stool and serum samples were obtained 6 months after 
completion of the patients chemotherapy, prior to IVIG 
administration to evaluate for any immune response as the 
patient continued to be symptomatic and B cell reconstitu-
tion would be expected to begin between 3 and 6 months 
after her last rituximab dose [9]. Further samples were 
obtained to monitor for evolution of titers when symp-
tom improvement and resolution were observed at 8 and 
10 months.
To identify the infecting viral strain, RNA was extracted 
from a stool sample using the QIAamp Viral RNA Mini Kit 
from Qiagen and a cDNA copy made for norovirus RT-
PCR 
using oligo dT as the primer. A strong RT-PCR band was 
visible by gel analysis with the GII primer set. This band 
was extracted and sequenced using norovirus capsid gene 
primers [10].
Surrogate neutralization assays were performed as 
described [3]. Briefly, patient serum or IVIG were seri-
ally diluted and mixed with VLP before adding the VLP 
to ligand coated plates and comparing the amount of VLP 
bound to gastric mucin in the presence of serum to the 
amount bound in the absence of serum. Reported titers are 
the reciprocal dilution of the percent serum needed to block 
50 % of VLP binding.
Results
Six months after completion of chemotherapy patient’s 
stool sample was positive for a genogroup II norovirus by 
RT-PCR. The infecting strain capsid sequence was 97 % 
homologous to norovirus GII.4-2009, the New Orleans 
strain [11]. A concomitant serum sample lacked the ability 
to block GII.4-2009 interaction with carbohydrate ligand 
in surrogate neutralization assays at 10 % serum (Fig. 1), 
as did aliquots of the administered IVIG batches (data not 
shown).
Eight months after chemotherapy completion patient’s 
serum showed an increased blockade titer (EC50 15.3) that 
correlated clinically with the ability to taper the antidiar-
rheal medication. At 10 months patient’s serum completely 
Fig. 1  Norovirus GII.4.2009 
polymerase chain reaction 
(PCR) negativity correlates 
with increased strain-specific 
blockade titer (filled square). 
Blockade titer is the reciprocal 
of the dilution of serum that 
blocked 50 % of GII.4.2009 
binding to carbohydrate ligand. 
Measurements of total immuno-
globulin G (IgG), white blood 
count (WBC), absolute neutro-
phil count (ANC) and absolute 
lymphocyte count (ALC) were 
not associated with symptom 
resolution
blocked the GII.4.2009 VLP interaction with ligand (EC50 
54.9), and she had returned to her normal stool pattern. A 
concomitant stool sample was negative for norovirus using 
the same RT-PCR protocol as for the 6-month stool sample. 
Total white blood count, absolute neutrophil and lympho-
cyte counts were not associated with symptom relief.
Discussion
We herein describe the emergence of norovirus strain-spe-
cific antibody blockade titers over time and their correla-
tion with decreased clinical symptoms in a case of pro-
longed diarrhea in the setting of rituximab–bendamustine 
chemotherapy for non-Hodgkin’s lymphoma.
Human mechanisms for protective immunity and clear-
ance of noroviruses are not well defined, but cellular and 
humoral immunity are hypothesized to play a role in viral 
clearance [12]. Both pathways of immunity are disturbed 
after rituximab-bendamustine chemotherapy [9, 13]; rituxi-
mab can deplete B-cells for 3–12 months [9]. B cell recov-
ery following rituximab in lymphoma is associated with 
a lasting preponderance of immature transitional B cells 
and a paucity of memory B cells [9]. This effect might 
explain the prolonged illness in our patient who continued 
treatment after the onset of her illness. No other cases of 
chronic Norovirus disease after bendamustin–rituximab 
chemotherapy have been described to date.
As in healthy volunteers, rising antibody blockade 
titers correlated with decreased diarrhea symptoms in our 
immunocompromised patient [6, 7]. This observation is of 
particular interest for patients after small bowel transplan-
tation. In these patients it can be difficult to differentiate 
an alloimune reaction from a symptomatic norovirus infec-
tion, and subsequently to decide between augmentation 
versus reduction of immunosuppression. Histopathology 
may not definitively differentiate between either diagnosis 
as inflammation and crypt apoptosis can be found in both 
processes [14].
Patients who undergo hematopoetic stem-cell transplan-
tation (HSCT) can have prolonged diarrheal illness in the 
setting of norovirus infection [4]. A semi-quantitative poly-
merase chain reaction has been used as a marker to distin-
guish asymptomatic from symptomatic norovirus infection 
post-HSCT [4], however this method is flawed as high fecal 
viral loads have also been demonstrated in asymptomatic 
healthy volunteers after norovirus challenge [15]. Studies 
in immunocompromised hosts evaluating the incidence of 
asymptomatic norovirus shedding are currently lacking. 
The absence of strain-specific antibody blockade titers in 
immunocompromised hosts could suggest norovirus infec-
tion as the cause of diarrhea. Complete antibody blockade 
would favor asymptomatic shedding and a different cause 
of the diarrhea than norovirus infection.
Nitazoxanide use was associated with improvement in 
norovirus gastroenteretis in a single immunocompromised 
patient [8]. In our patient nitazoxande was ineffective. To 
evaluate whether immune reconstitution plays a role in 
symptom improvement when using off label or novel thera-
peutics for norovirus infection in immunocompromised 
hosts antibody blockade titers could be helpful. Adminis-
tration of IVIG that was devoid of strain-specific block-
ade titer was also an ineffective treatment, supporting the 
association between strain-specific blockade IgG titer and 
symptom relief. These findings suggest that IVIG may not 
be an effective treatment for norovirus infection for newly 
emergent strains, as herd immunity to these strains will not 
yet have been established. Consequently, development of 
human monoclonal antibodies with cross-strain blockade 
activity may provide effective treatment for symptomatic 
norovirus infection, as recently suggested [3].
In conclusion, rising strain-specific antibody blockade 
titers correlated with symptom resolution in an immuno-
compromised patient with chronic norovirus disease. Treat-
ment with rituximab or with other agents that impair B-cell 
responses may lead to protracted diarrheal illnesses.
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